Document Type
Article
Publication Date
5-22-2017
Abstract
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially. The clinical efficacy and the inhibition of radiographic progression demonstrated by TNFi have transformed the management of PsA. However, there is still an unmet need for a subset of patients who do not respond adequately to TNFi. Areas covered: This review provides an overview of the pharmacokinetics of TNFi, the efficacy of TNFi in PsA, and the role of immunogenicity of TNFi in the treatment of PsA. In addition, we address the use of TNFi in the setting of other medications utilized in the treatment of PsA and the potential future role of biosimilars. Expert commentary: Monoclonal antibodies exhibit complex and widely variable pharmacokinetics. The study of factors that can affect the pharmacokinetics, such as immunogenicity, is valuable to further define and understand the use of TNFi in PsA, especially in the subset of patients who do not respond adequately to these agents or lose effectiveness over time.
Recommended Citation
Mantravadi, Santhi; Ogdie, Alexis; and Kraft, Walter K., "Tumor necrosis factor inhibitors in psoriatic arthritis." (2017). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 81.
https://jdc.jefferson.edu/petfp/81
PubMed ID
28490202
Comments
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology on May 22, 2017, available online: http://www.tandfonline.com/10.1080/17512433.2017.1329009